Global Immuno-oncology Diagnosis Supply, Demand and Key Producers, 2026-2032
The global Immuno-oncology Diagnosis market size is expected to reach $ 20814 million by 2032, rising at a market growth of 12.3% CAGR during the forecast period (2026-2032).
Immuno-oncology diagnostics refers to a comprehensive system of precise detection and evaluation technologies surrounding tumor immunotherapy. Its core lies in detecting key biomarkers in tumors and their immune microenvironment, combined with molecular diagnostics, immunohistochemistry, and next-generation sequencing to screen patients for suitability for immunotherapies such as Immune Checkpoint Inhibitors, predict efficacy, and dynamically monitor their progress. This enables integrated, personalized treatment decisions encompassing diagnosis, medication, and efficacy evaluation, making it a crucial entry point technology within the precision medicine
The growth logic of immuno-oncology diagnostics is highly dependent on the expansion of tumor immunotherapy. With the continuous expansion of the indications for immunotherapies such as PD-1/PD-L1 in multiple cancer types, and the emergence of new therapies such as CAR-T and bispecific antibodies, the demand for precise patient screening and companion diagnostics is rapidly increasing. At the same time, the industry is upgrading from single biomarker detection to multi-omics integrated analysis, and the combination of liquid biopsy and AI algorithms is driving the trend of 'non-invasive + dynamic' monitoring, significantly improving clinical value and frequency of use. At the regulatory level, the 'drug + diagnostic' collaborative approval model is being strengthened, forming a deep bond between leading diagnostic companies and pharmaceutical companies, further raising industry barriers. It is expected that this field will continue to maintain medium-to-high-speed growth in the next 5-10 years, becoming one of the most core infrastructures in the precision medicine and cancer treatment system.
This report studies the global Immuno-oncology Diagnosis demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Immuno-oncology Diagnosis, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Immuno-oncology Diagnosis that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Immuno-oncology Diagnosis total market, 2021-2032, (USD Million)
Global Immuno-oncology Diagnosis total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Immuno-oncology Diagnosis total market, key domestic companies, and share, (USD Million)
Global Immuno-oncology Diagnosis revenue by player, revenue and market share 2021-2026, (USD Million)
Global Immuno-oncology Diagnosis total market by Technology Path, CAGR, 2021-2032, (USD Million)
Global Immuno-oncology Diagnosis total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Immuno-oncology Diagnosis market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Guardant Health (USA), Foundation Medicine (USA), Illumina (USA), Thermo Fisher Scientific (USA), LabCorp (USA), NeoGenomics (USA), Myriad Genetics (USA), Caris Life Sciences (USA), Roche (Switzerland), BioM?rieux (France), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Immuno-oncology Diagnosis market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Technology Path, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Immuno-oncology Diagnosis Market, By Region:
1. How big is the global Immuno-oncology Diagnosis market?
2. What is the demand of the global Immuno-oncology Diagnosis market?
3. What is the year over year growth of the global Immuno-oncology Diagnosis market?
4. What is the total value of the global Immuno-oncology Diagnosis market?
5. Who are the Major Players in the global Immuno-oncology Diagnosis market?
6. What are the growth factors driving the market demand?
Immuno-oncology diagnostics refers to a comprehensive system of precise detection and evaluation technologies surrounding tumor immunotherapy. Its core lies in detecting key biomarkers in tumors and their immune microenvironment, combined with molecular diagnostics, immunohistochemistry, and next-generation sequencing to screen patients for suitability for immunotherapies such as Immune Checkpoint Inhibitors, predict efficacy, and dynamically monitor their progress. This enables integrated, personalized treatment decisions encompassing diagnosis, medication, and efficacy evaluation, making it a crucial entry point technology within the precision medicine
The growth logic of immuno-oncology diagnostics is highly dependent on the expansion of tumor immunotherapy. With the continuous expansion of the indications for immunotherapies such as PD-1/PD-L1 in multiple cancer types, and the emergence of new therapies such as CAR-T and bispecific antibodies, the demand for precise patient screening and companion diagnostics is rapidly increasing. At the same time, the industry is upgrading from single biomarker detection to multi-omics integrated analysis, and the combination of liquid biopsy and AI algorithms is driving the trend of 'non-invasive + dynamic' monitoring, significantly improving clinical value and frequency of use. At the regulatory level, the 'drug + diagnostic' collaborative approval model is being strengthened, forming a deep bond between leading diagnostic companies and pharmaceutical companies, further raising industry barriers. It is expected that this field will continue to maintain medium-to-high-speed growth in the next 5-10 years, becoming one of the most core infrastructures in the precision medicine and cancer treatment system.
This report studies the global Immuno-oncology Diagnosis demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Immuno-oncology Diagnosis, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Immuno-oncology Diagnosis that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Immuno-oncology Diagnosis total market, 2021-2032, (USD Million)
Global Immuno-oncology Diagnosis total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Immuno-oncology Diagnosis total market, key domestic companies, and share, (USD Million)
Global Immuno-oncology Diagnosis revenue by player, revenue and market share 2021-2026, (USD Million)
Global Immuno-oncology Diagnosis total market by Technology Path, CAGR, 2021-2032, (USD Million)
Global Immuno-oncology Diagnosis total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Immuno-oncology Diagnosis market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Guardant Health (USA), Foundation Medicine (USA), Illumina (USA), Thermo Fisher Scientific (USA), LabCorp (USA), NeoGenomics (USA), Myriad Genetics (USA), Caris Life Sciences (USA), Roche (Switzerland), BioM?rieux (France), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Immuno-oncology Diagnosis market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Technology Path, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Immuno-oncology Diagnosis Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Immunohistochemistry
- Molecular Diagnostics
- High-Throughput Sequencing
- Liquid Biopsy
- Multi-omics Integrated Analysis
- Immune Checkpoint Biomarkers
- Tumor Mutation Burden
- Microsatellite Instability
- Tumor-Infiltrating Lymphocytes
- Immune-Related Gene Expression Profiling
- Immunodiagnostics for Solid Tumors
- Immunodiagnostics for Hematologic Malignancies
- Tumor Microenvironment (TME) Analysis
- Research
- Diagnostics
- Guardant Health (USA)
- Foundation Medicine (USA)
- Illumina (USA)
- Thermo Fisher Scientific (USA)
- LabCorp (USA)
- NeoGenomics (USA)
- Myriad Genetics (USA)
- Caris Life Sciences (USA)
- Roche (Switzerland)
- BioM?rieux (France)
- QIAGEN (Netherlands)
- Burning Rock Biotech (China)
- Novogene (China)
- BGI Genomics (China)
- Sysmex (Japan)
- Fujirebio (Japan)
- IMBDx (South Korea)
- Seegene (South Korea)
- GeneMatrix (South Korea)
1. How big is the global Immuno-oncology Diagnosis market?
2. What is the demand of the global Immuno-oncology Diagnosis market?
3. What is the year over year growth of the global Immuno-oncology Diagnosis market?
4. What is the total value of the global Immuno-oncology Diagnosis market?
5. Who are the Major Players in the global Immuno-oncology Diagnosis market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Immuno-oncology Diagnosis Introduction
1.2 World Immuno-oncology Diagnosis Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Immuno-oncology Diagnosis Total Market by Region (by Headquarter Location)
1.3.1 World Immuno-oncology Diagnosis Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.3 China Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.4 Europe Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.5 Japan Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.6 South Korea Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.7 ASEAN Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.8 India Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Immuno-oncology Diagnosis Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.2 World Immuno-oncology Diagnosis Consumption Value by Region
2.2.1 World Immuno-oncology Diagnosis Consumption Value by Region (2021-2026)
2.2.2 World Immuno-oncology Diagnosis Consumption Value Forecast by Region (2027-2032)
2.3 United States Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.4 China Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.5 Europe Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.6 Japan Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.7 South Korea Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.8 ASEAN Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.9 India Immuno-oncology Diagnosis Consumption Value (2021-2032)
3 WORLD IMMUNO-ONCOLOGY DIAGNOSIS COMPANIES COMPETITIVE ANALYSIS
3.1 World Immuno-oncology Diagnosis Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Immuno-oncology Diagnosis Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Immuno-oncology Diagnosis in 2025
3.2.3 Global Concentration Ratios (CR8) for Immuno-oncology Diagnosis in 2025
3.3 Immuno-oncology Diagnosis Company Evaluation Quadrant
3.4 Immuno-oncology Diagnosis Market: Overall Company Footprint Analysis
3.4.1 Immuno-oncology Diagnosis Market: Region Footprint
3.4.2 Immuno-oncology Diagnosis Market: Company Product Type Footprint
3.4.3 Immuno-oncology Diagnosis Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Immuno-oncology Diagnosis Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Immuno-oncology Diagnosis Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Immuno-oncology Diagnosis Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Immuno-oncology Diagnosis Consumption Value Comparison
4.2.1 United States VS China: Immuno-oncology Diagnosis Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Immuno-oncology Diagnosis Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Immuno-oncology Diagnosis Companies and Market Share, 2021-2026
4.3.1 United States Based Immuno-oncology Diagnosis Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Immuno-oncology Diagnosis Revenue, (2021-2026)
4.4 China Based Companies Immuno-oncology Diagnosis Revenue and Market Share, 2021-2026
4.4.1 China Based Immuno-oncology Diagnosis Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Immuno-oncology Diagnosis Revenue, (2021-2026)
4.5 Rest of World Based Immuno-oncology Diagnosis Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Immuno-oncology Diagnosis Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Immuno-oncology Diagnosis Revenue (2021-2026)
5 MARKET ANALYSIS BY TECHNOLOGY PATH
5.1 World Immuno-oncology Diagnosis Market Size Overview by Technology Path: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Technology Path
5.2.1 Immunohistochemistry
5.2.2 Molecular Diagnostics
5.2.3 High-Throughput Sequencing
5.2.4 Liquid Biopsy
5.2.5 Multi-omics Integrated Analysis
5.3 Market Segment by Technology Path
5.3.1 World Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
5.3.2 World Immuno-oncology Diagnosis Market Size by Technology Path (2027-2032)
5.3.3 World Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2027-2032)
6 MARKET ANALYSIS BY DETECTION BIOMARKERS
6.1 World Immuno-oncology Diagnosis Market Size Overview by Detection Biomarkers: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Detection Biomarkers
6.2.1 Immune Checkpoint Biomarkers
6.2.2 Tumor Mutation Burden
6.2.3 Microsatellite Instability
6.2.4 Tumor-Infiltrating Lymphocytes
6.2.5 Immune-Related Gene Expression Profiling
6.3 Market Segment by Detection Biomarkers
6.3.1 World Immuno-oncology Diagnosis Market Size by Detection Biomarkers (2021-2026)
6.3.2 World Immuno-oncology Diagnosis Market Size by Detection Biomarkers (2027-2032)
6.3.3 World Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers (2027-2032)
7 MARKET ANALYSIS BY USE SCENARIOS
7.1 World Immuno-oncology Diagnosis Market Size Overview by Use Scenarios: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Use Scenarios
7.2.1 Immunodiagnostics for Solid Tumors
7.2.2 Immunodiagnostics for Hematologic Malignancies
7.2.3 Tumor Microenvironment (TME) Analysis
7.3 Market Segment by Use Scenarios
7.3.1 World Immuno-oncology Diagnosis Market Size by Use Scenarios (2021-2026)
7.3.2 World Immuno-oncology Diagnosis Market Size by Use Scenarios (2027-2032)
7.3.3 World Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Immuno-oncology Diagnosis Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Research
8.2.2 Diagnostics
8.3 Market Segment by Application
8.3.1 World Immuno-oncology Diagnosis Market Size by Application (2021-2026)
8.3.2 World Immuno-oncology Diagnosis Market Size by Application (2027-2032)
8.3.3 World Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Guardant Health (USA)
9.1.1 Guardant Health (USA) Details
9.1.2 Guardant Health (USA) Major Business
9.1.3 Guardant Health (USA) Immuno-oncology Diagnosis Product and Services
9.1.4 Guardant Health (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Guardant Health (USA) Recent Developments/Updates
9.1.6 Guardant Health (USA) Competitive Strengths & Weaknesses
9.2 Foundation Medicine (USA)
9.2.1 Foundation Medicine (USA) Details
9.2.2 Foundation Medicine (USA) Major Business
9.2.3 Foundation Medicine (USA) Immuno-oncology Diagnosis Product and Services
9.2.4 Foundation Medicine (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Foundation Medicine (USA) Recent Developments/Updates
9.2.6 Foundation Medicine (USA) Competitive Strengths & Weaknesses
9.3 Illumina (USA)
9.3.1 Illumina (USA) Details
9.3.2 Illumina (USA) Major Business
9.3.3 Illumina (USA) Immuno-oncology Diagnosis Product and Services
9.3.4 Illumina (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Illumina (USA) Recent Developments/Updates
9.3.6 Illumina (USA) Competitive Strengths & Weaknesses
9.4 Thermo Fisher Scientific (USA)
9.4.1 Thermo Fisher Scientific (USA) Details
9.4.2 Thermo Fisher Scientific (USA) Major Business
9.4.3 Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Product and Services
9.4.4 Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Thermo Fisher Scientific (USA) Recent Developments/Updates
9.4.6 Thermo Fisher Scientific (USA) Competitive Strengths & Weaknesses
9.5 LabCorp (USA)
9.5.1 LabCorp (USA) Details
9.5.2 LabCorp (USA) Major Business
9.5.3 LabCorp (USA) Immuno-oncology Diagnosis Product and Services
9.5.4 LabCorp (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 LabCorp (USA) Recent Developments/Updates
9.5.6 LabCorp (USA) Competitive Strengths & Weaknesses
9.6 NeoGenomics (USA)
9.6.1 NeoGenomics (USA) Details
9.6.2 NeoGenomics (USA) Major Business
9.6.3 NeoGenomics (USA) Immuno-oncology Diagnosis Product and Services
9.6.4 NeoGenomics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 NeoGenomics (USA) Recent Developments/Updates
9.6.6 NeoGenomics (USA) Competitive Strengths & Weaknesses
9.7 Myriad Genetics (USA)
9.7.1 Myriad Genetics (USA) Details
9.7.2 Myriad Genetics (USA) Major Business
9.7.3 Myriad Genetics (USA) Immuno-oncology Diagnosis Product and Services
9.7.4 Myriad Genetics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Myriad Genetics (USA) Recent Developments/Updates
9.7.6 Myriad Genetics (USA) Competitive Strengths & Weaknesses
9.8 Caris Life Sciences (USA)
9.8.1 Caris Life Sciences (USA) Details
9.8.2 Caris Life Sciences (USA) Major Business
9.8.3 Caris Life Sciences (USA) Immuno-oncology Diagnosis Product and Services
9.8.4 Caris Life Sciences (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Caris Life Sciences (USA) Recent Developments/Updates
9.8.6 Caris Life Sciences (USA) Competitive Strengths & Weaknesses
9.9 Roche (Switzerland)
9.9.1 Roche (Switzerland) Details
9.9.2 Roche (Switzerland) Major Business
9.9.3 Roche (Switzerland) Immuno-oncology Diagnosis Product and Services
9.9.4 Roche (Switzerland) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Roche (Switzerland) Recent Developments/Updates
9.9.6 Roche (Switzerland) Competitive Strengths & Weaknesses
9.10 BioM?rieux (France)
9.10.1 BioM?rieux (France) Details
9.10.2 BioM?rieux (France) Major Business
9.10.3 BioM?rieux (France) Immuno-oncology Diagnosis Product and Services
9.10.4 BioM?rieux (France) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 BioM?rieux (France) Recent Developments/Updates
9.10.6 BioM?rieux (France) Competitive Strengths & Weaknesses
9.11 QIAGEN (Netherlands)
9.11.1 QIAGEN (Netherlands) Details
9.11.2 QIAGEN (Netherlands) Major Business
9.11.3 QIAGEN (Netherlands) Immuno-oncology Diagnosis Product and Services
9.11.4 QIAGEN (Netherlands) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 QIAGEN (Netherlands) Recent Developments/Updates
9.11.6 QIAGEN (Netherlands) Competitive Strengths & Weaknesses
9.12 Burning Rock Biotech (China)
9.12.1 Burning Rock Biotech (China) Details
9.12.2 Burning Rock Biotech (China) Major Business
9.12.3 Burning Rock Biotech (China) Immuno-oncology Diagnosis Product and Services
9.12.4 Burning Rock Biotech (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Burning Rock Biotech (China) Recent Developments/Updates
9.12.6 Burning Rock Biotech (China) Competitive Strengths & Weaknesses
9.13 Novogene (China)
9.13.1 Novogene (China) Details
9.13.2 Novogene (China) Major Business
9.13.3 Novogene (China) Immuno-oncology Diagnosis Product and Services
9.13.4 Novogene (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Novogene (China) Recent Developments/Updates
9.13.6 Novogene (China) Competitive Strengths & Weaknesses
9.14 BGI Genomics (China)
9.14.1 BGI Genomics (China) Details
9.14.2 BGI Genomics (China) Major Business
9.14.3 BGI Genomics (China) Immuno-oncology Diagnosis Product and Services
9.14.4 BGI Genomics (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 BGI Genomics (China) Recent Developments/Updates
9.14.6 BGI Genomics (China) Competitive Strengths & Weaknesses
9.15 Sysmex (Japan)
9.15.1 Sysmex (Japan) Details
9.15.2 Sysmex (Japan) Major Business
9.15.3 Sysmex (Japan) Immuno-oncology Diagnosis Product and Services
9.15.4 Sysmex (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Sysmex (Japan) Recent Developments/Updates
9.15.6 Sysmex (Japan) Competitive Strengths & Weaknesses
9.16 Fujirebio (Japan)
9.16.1 Fujirebio (Japan) Details
9.16.2 Fujirebio (Japan) Major Business
9.16.3 Fujirebio (Japan) Immuno-oncology Diagnosis Product and Services
9.16.4 Fujirebio (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Fujirebio (Japan) Recent Developments/Updates
9.16.6 Fujirebio (Japan) Competitive Strengths & Weaknesses
9.17 IMBDx (South Korea)
9.17.1 IMBDx (South Korea) Details
9.17.2 IMBDx (South Korea) Major Business
9.17.3 IMBDx (South Korea) Immuno-oncology Diagnosis Product and Services
9.17.4 IMBDx (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 IMBDx (South Korea) Recent Developments/Updates
9.17.6 IMBDx (South Korea) Competitive Strengths & Weaknesses
9.18 Seegene (South Korea)
9.18.1 Seegene (South Korea) Details
9.18.2 Seegene (South Korea) Major Business
9.18.3 Seegene (South Korea) Immuno-oncology Diagnosis Product and Services
9.18.4 Seegene (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Seegene (South Korea) Recent Developments/Updates
9.18.6 Seegene (South Korea) Competitive Strengths & Weaknesses
9.19 GeneMatrix (South Korea)
9.19.1 GeneMatrix (South Korea) Details
9.19.2 GeneMatrix (South Korea) Major Business
9.19.3 GeneMatrix (South Korea) Immuno-oncology Diagnosis Product and Services
9.19.4 GeneMatrix (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 GeneMatrix (South Korea) Recent Developments/Updates
9.19.6 GeneMatrix (South Korea) Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Immuno-oncology Diagnosis Industry Chain
10.2 Immuno-oncology Diagnosis Upstream Analysis
10.3 Immuno-oncology Diagnosis Midstream Analysis
10.4 Immuno-oncology Diagnosis Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Immuno-oncology Diagnosis Introduction
1.2 World Immuno-oncology Diagnosis Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Immuno-oncology Diagnosis Total Market by Region (by Headquarter Location)
1.3.1 World Immuno-oncology Diagnosis Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.3 China Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.4 Europe Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.5 Japan Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.6 South Korea Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.7 ASEAN Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.3.8 India Based Company Immuno-oncology Diagnosis Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Immuno-oncology Diagnosis Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.2 World Immuno-oncology Diagnosis Consumption Value by Region
2.2.1 World Immuno-oncology Diagnosis Consumption Value by Region (2021-2026)
2.2.2 World Immuno-oncology Diagnosis Consumption Value Forecast by Region (2027-2032)
2.3 United States Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.4 China Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.5 Europe Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.6 Japan Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.7 South Korea Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.8 ASEAN Immuno-oncology Diagnosis Consumption Value (2021-2032)
2.9 India Immuno-oncology Diagnosis Consumption Value (2021-2032)
3 WORLD IMMUNO-ONCOLOGY DIAGNOSIS COMPANIES COMPETITIVE ANALYSIS
3.1 World Immuno-oncology Diagnosis Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Immuno-oncology Diagnosis Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Immuno-oncology Diagnosis in 2025
3.2.3 Global Concentration Ratios (CR8) for Immuno-oncology Diagnosis in 2025
3.3 Immuno-oncology Diagnosis Company Evaluation Quadrant
3.4 Immuno-oncology Diagnosis Market: Overall Company Footprint Analysis
3.4.1 Immuno-oncology Diagnosis Market: Region Footprint
3.4.2 Immuno-oncology Diagnosis Market: Company Product Type Footprint
3.4.3 Immuno-oncology Diagnosis Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Immuno-oncology Diagnosis Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Immuno-oncology Diagnosis Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Immuno-oncology Diagnosis Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Immuno-oncology Diagnosis Consumption Value Comparison
4.2.1 United States VS China: Immuno-oncology Diagnosis Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Immuno-oncology Diagnosis Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Immuno-oncology Diagnosis Companies and Market Share, 2021-2026
4.3.1 United States Based Immuno-oncology Diagnosis Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Immuno-oncology Diagnosis Revenue, (2021-2026)
4.4 China Based Companies Immuno-oncology Diagnosis Revenue and Market Share, 2021-2026
4.4.1 China Based Immuno-oncology Diagnosis Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Immuno-oncology Diagnosis Revenue, (2021-2026)
4.5 Rest of World Based Immuno-oncology Diagnosis Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Immuno-oncology Diagnosis Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Immuno-oncology Diagnosis Revenue (2021-2026)
5 MARKET ANALYSIS BY TECHNOLOGY PATH
5.1 World Immuno-oncology Diagnosis Market Size Overview by Technology Path: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Technology Path
5.2.1 Immunohistochemistry
5.2.2 Molecular Diagnostics
5.2.3 High-Throughput Sequencing
5.2.4 Liquid Biopsy
5.2.5 Multi-omics Integrated Analysis
5.3 Market Segment by Technology Path
5.3.1 World Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
5.3.2 World Immuno-oncology Diagnosis Market Size by Technology Path (2027-2032)
5.3.3 World Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2027-2032)
6 MARKET ANALYSIS BY DETECTION BIOMARKERS
6.1 World Immuno-oncology Diagnosis Market Size Overview by Detection Biomarkers: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Detection Biomarkers
6.2.1 Immune Checkpoint Biomarkers
6.2.2 Tumor Mutation Burden
6.2.3 Microsatellite Instability
6.2.4 Tumor-Infiltrating Lymphocytes
6.2.5 Immune-Related Gene Expression Profiling
6.3 Market Segment by Detection Biomarkers
6.3.1 World Immuno-oncology Diagnosis Market Size by Detection Biomarkers (2021-2026)
6.3.2 World Immuno-oncology Diagnosis Market Size by Detection Biomarkers (2027-2032)
6.3.3 World Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers (2027-2032)
7 MARKET ANALYSIS BY USE SCENARIOS
7.1 World Immuno-oncology Diagnosis Market Size Overview by Use Scenarios: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Use Scenarios
7.2.1 Immunodiagnostics for Solid Tumors
7.2.2 Immunodiagnostics for Hematologic Malignancies
7.2.3 Tumor Microenvironment (TME) Analysis
7.3 Market Segment by Use Scenarios
7.3.1 World Immuno-oncology Diagnosis Market Size by Use Scenarios (2021-2026)
7.3.2 World Immuno-oncology Diagnosis Market Size by Use Scenarios (2027-2032)
7.3.3 World Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Immuno-oncology Diagnosis Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Research
8.2.2 Diagnostics
8.3 Market Segment by Application
8.3.1 World Immuno-oncology Diagnosis Market Size by Application (2021-2026)
8.3.2 World Immuno-oncology Diagnosis Market Size by Application (2027-2032)
8.3.3 World Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Guardant Health (USA)
9.1.1 Guardant Health (USA) Details
9.1.2 Guardant Health (USA) Major Business
9.1.3 Guardant Health (USA) Immuno-oncology Diagnosis Product and Services
9.1.4 Guardant Health (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Guardant Health (USA) Recent Developments/Updates
9.1.6 Guardant Health (USA) Competitive Strengths & Weaknesses
9.2 Foundation Medicine (USA)
9.2.1 Foundation Medicine (USA) Details
9.2.2 Foundation Medicine (USA) Major Business
9.2.3 Foundation Medicine (USA) Immuno-oncology Diagnosis Product and Services
9.2.4 Foundation Medicine (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Foundation Medicine (USA) Recent Developments/Updates
9.2.6 Foundation Medicine (USA) Competitive Strengths & Weaknesses
9.3 Illumina (USA)
9.3.1 Illumina (USA) Details
9.3.2 Illumina (USA) Major Business
9.3.3 Illumina (USA) Immuno-oncology Diagnosis Product and Services
9.3.4 Illumina (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Illumina (USA) Recent Developments/Updates
9.3.6 Illumina (USA) Competitive Strengths & Weaknesses
9.4 Thermo Fisher Scientific (USA)
9.4.1 Thermo Fisher Scientific (USA) Details
9.4.2 Thermo Fisher Scientific (USA) Major Business
9.4.3 Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Product and Services
9.4.4 Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Thermo Fisher Scientific (USA) Recent Developments/Updates
9.4.6 Thermo Fisher Scientific (USA) Competitive Strengths & Weaknesses
9.5 LabCorp (USA)
9.5.1 LabCorp (USA) Details
9.5.2 LabCorp (USA) Major Business
9.5.3 LabCorp (USA) Immuno-oncology Diagnosis Product and Services
9.5.4 LabCorp (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 LabCorp (USA) Recent Developments/Updates
9.5.6 LabCorp (USA) Competitive Strengths & Weaknesses
9.6 NeoGenomics (USA)
9.6.1 NeoGenomics (USA) Details
9.6.2 NeoGenomics (USA) Major Business
9.6.3 NeoGenomics (USA) Immuno-oncology Diagnosis Product and Services
9.6.4 NeoGenomics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 NeoGenomics (USA) Recent Developments/Updates
9.6.6 NeoGenomics (USA) Competitive Strengths & Weaknesses
9.7 Myriad Genetics (USA)
9.7.1 Myriad Genetics (USA) Details
9.7.2 Myriad Genetics (USA) Major Business
9.7.3 Myriad Genetics (USA) Immuno-oncology Diagnosis Product and Services
9.7.4 Myriad Genetics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Myriad Genetics (USA) Recent Developments/Updates
9.7.6 Myriad Genetics (USA) Competitive Strengths & Weaknesses
9.8 Caris Life Sciences (USA)
9.8.1 Caris Life Sciences (USA) Details
9.8.2 Caris Life Sciences (USA) Major Business
9.8.3 Caris Life Sciences (USA) Immuno-oncology Diagnosis Product and Services
9.8.4 Caris Life Sciences (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Caris Life Sciences (USA) Recent Developments/Updates
9.8.6 Caris Life Sciences (USA) Competitive Strengths & Weaknesses
9.9 Roche (Switzerland)
9.9.1 Roche (Switzerland) Details
9.9.2 Roche (Switzerland) Major Business
9.9.3 Roche (Switzerland) Immuno-oncology Diagnosis Product and Services
9.9.4 Roche (Switzerland) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Roche (Switzerland) Recent Developments/Updates
9.9.6 Roche (Switzerland) Competitive Strengths & Weaknesses
9.10 BioM?rieux (France)
9.10.1 BioM?rieux (France) Details
9.10.2 BioM?rieux (France) Major Business
9.10.3 BioM?rieux (France) Immuno-oncology Diagnosis Product and Services
9.10.4 BioM?rieux (France) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 BioM?rieux (France) Recent Developments/Updates
9.10.6 BioM?rieux (France) Competitive Strengths & Weaknesses
9.11 QIAGEN (Netherlands)
9.11.1 QIAGEN (Netherlands) Details
9.11.2 QIAGEN (Netherlands) Major Business
9.11.3 QIAGEN (Netherlands) Immuno-oncology Diagnosis Product and Services
9.11.4 QIAGEN (Netherlands) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 QIAGEN (Netherlands) Recent Developments/Updates
9.11.6 QIAGEN (Netherlands) Competitive Strengths & Weaknesses
9.12 Burning Rock Biotech (China)
9.12.1 Burning Rock Biotech (China) Details
9.12.2 Burning Rock Biotech (China) Major Business
9.12.3 Burning Rock Biotech (China) Immuno-oncology Diagnosis Product and Services
9.12.4 Burning Rock Biotech (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Burning Rock Biotech (China) Recent Developments/Updates
9.12.6 Burning Rock Biotech (China) Competitive Strengths & Weaknesses
9.13 Novogene (China)
9.13.1 Novogene (China) Details
9.13.2 Novogene (China) Major Business
9.13.3 Novogene (China) Immuno-oncology Diagnosis Product and Services
9.13.4 Novogene (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Novogene (China) Recent Developments/Updates
9.13.6 Novogene (China) Competitive Strengths & Weaknesses
9.14 BGI Genomics (China)
9.14.1 BGI Genomics (China) Details
9.14.2 BGI Genomics (China) Major Business
9.14.3 BGI Genomics (China) Immuno-oncology Diagnosis Product and Services
9.14.4 BGI Genomics (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 BGI Genomics (China) Recent Developments/Updates
9.14.6 BGI Genomics (China) Competitive Strengths & Weaknesses
9.15 Sysmex (Japan)
9.15.1 Sysmex (Japan) Details
9.15.2 Sysmex (Japan) Major Business
9.15.3 Sysmex (Japan) Immuno-oncology Diagnosis Product and Services
9.15.4 Sysmex (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Sysmex (Japan) Recent Developments/Updates
9.15.6 Sysmex (Japan) Competitive Strengths & Weaknesses
9.16 Fujirebio (Japan)
9.16.1 Fujirebio (Japan) Details
9.16.2 Fujirebio (Japan) Major Business
9.16.3 Fujirebio (Japan) Immuno-oncology Diagnosis Product and Services
9.16.4 Fujirebio (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Fujirebio (Japan) Recent Developments/Updates
9.16.6 Fujirebio (Japan) Competitive Strengths & Weaknesses
9.17 IMBDx (South Korea)
9.17.1 IMBDx (South Korea) Details
9.17.2 IMBDx (South Korea) Major Business
9.17.3 IMBDx (South Korea) Immuno-oncology Diagnosis Product and Services
9.17.4 IMBDx (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 IMBDx (South Korea) Recent Developments/Updates
9.17.6 IMBDx (South Korea) Competitive Strengths & Weaknesses
9.18 Seegene (South Korea)
9.18.1 Seegene (South Korea) Details
9.18.2 Seegene (South Korea) Major Business
9.18.3 Seegene (South Korea) Immuno-oncology Diagnosis Product and Services
9.18.4 Seegene (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Seegene (South Korea) Recent Developments/Updates
9.18.6 Seegene (South Korea) Competitive Strengths & Weaknesses
9.19 GeneMatrix (South Korea)
9.19.1 GeneMatrix (South Korea) Details
9.19.2 GeneMatrix (South Korea) Major Business
9.19.3 GeneMatrix (South Korea) Immuno-oncology Diagnosis Product and Services
9.19.4 GeneMatrix (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 GeneMatrix (South Korea) Recent Developments/Updates
9.19.6 GeneMatrix (South Korea) Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Immuno-oncology Diagnosis Industry Chain
10.2 Immuno-oncology Diagnosis Upstream Analysis
10.3 Immuno-oncology Diagnosis Midstream Analysis
10.4 Immuno-oncology Diagnosis Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Immuno-oncology Diagnosis Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Immuno-oncology Diagnosis Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Immuno-oncology Diagnosis Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Immuno-oncology Diagnosis Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Immuno-oncology Diagnosis Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Immuno-oncology Diagnosis Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Immuno-oncology Diagnosis Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Immuno-oncology Diagnosis Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Immuno-oncology Diagnosis Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Immuno-oncology Diagnosis Players in 2025
Table 12. World Immuno-oncology Diagnosis Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Immuno-oncology Diagnosis Company Evaluation Quadrant
Table 14. Head Office of Key Immuno-oncology Diagnosis Players
Table 15. Immuno-oncology Diagnosis Market: Company Product Type Footprint
Table 16. Immuno-oncology Diagnosis Market: Company Product Application Footprint
Table 17. Immuno-oncology Diagnosis Mergers & Acquisitions Activity
Table 18. United States VS China Immuno-oncology Diagnosis Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Immuno-oncology Diagnosis Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Immuno-oncology Diagnosis Companies, Headquarters (States, Country)
Table 21. United States Based Companies Immuno-oncology Diagnosis Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Immuno-oncology Diagnosis Revenue Market Share (2021-2026)
Table 23. China Based Immuno-oncology Diagnosis Companies, Headquarters (Province, Country)
Table 24. China Based Companies Immuno-oncology Diagnosis Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Immuno-oncology Diagnosis Revenue Market Share (2021-2026)
Table 26. Rest of World Based Immuno-oncology Diagnosis Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Immuno-oncology Diagnosis Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Immuno-oncology Diagnosis Revenue Market Share (2021-2026)
Table 29. World Immuno-oncology Diagnosis Market Size by Technology Path, (USD Million), 2021 & 2025 & 2032
Table 30. World Immuno-oncology Diagnosis Market Size Value by Technology Path (2021-2026) & (USD Million)
Table 31. World Immuno-oncology Diagnosis Market Size by Technology Path (2027-2032) & (USD Million)
Table 32. World Immuno-oncology Diagnosis Market Size by Detection Biomarkers, (USD Million), 2021 & 2025 & 2032
Table 33. World Immuno-oncology Diagnosis Market Size Value by Detection Biomarkers (2021-2026) & (USD Million)
Table 34. World Immuno-oncology Diagnosis Market Size by Detection Biomarkers (2027-2032) & (USD Million)
Table 35. World Immuno-oncology Diagnosis Market Size by Use Scenarios, (USD Million), 2021 & 2025 & 2032
Table 36. World Immuno-oncology Diagnosis Market Size Value by Use Scenarios (2021-2026) & (USD Million)
Table 37. World Immuno-oncology Diagnosis Market Size by Use Scenarios (2027-2032) & (USD Million)
Table 38. World Immuno-oncology Diagnosis Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Immuno-oncology Diagnosis Market Size by Application (2021-2026) & (USD Million)
Table 40. World Immuno-oncology Diagnosis Market Size by Application (2027-2032) & (USD Million)
Table 41. Guardant Health (USA) Basic Information, Manufacturing Base and Competitors
Table 42. Guardant Health (USA) Major Business
Table 43. Guardant Health (USA) Immuno-oncology Diagnosis Product and Services
Table 44. Guardant Health (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Guardant Health (USA) Recent Developments/Updates
Table 46. Guardant Health (USA) Competitive Strengths & Weaknesses
Table 47. Foundation Medicine (USA) Basic Information, Manufacturing Base and Competitors
Table 48. Foundation Medicine (USA) Major Business
Table 49. Foundation Medicine (USA) Immuno-oncology Diagnosis Product and Services
Table 50. Foundation Medicine (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Foundation Medicine (USA) Recent Developments/Updates
Table 52. Foundation Medicine (USA) Competitive Strengths & Weaknesses
Table 53. Illumina (USA) Basic Information, Manufacturing Base and Competitors
Table 54. Illumina (USA) Major Business
Table 55. Illumina (USA) Immuno-oncology Diagnosis Product and Services
Table 56. Illumina (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Illumina (USA) Recent Developments/Updates
Table 58. Illumina (USA) Competitive Strengths & Weaknesses
Table 59. Thermo Fisher Scientific (USA) Basic Information, Manufacturing Base and Competitors
Table 60. Thermo Fisher Scientific (USA) Major Business
Table 61. Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Product and Services
Table 62. Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Thermo Fisher Scientific (USA) Recent Developments/Updates
Table 64. Thermo Fisher Scientific (USA) Competitive Strengths & Weaknesses
Table 65. LabCorp (USA) Basic Information, Manufacturing Base and Competitors
Table 66. LabCorp (USA) Major Business
Table 67. LabCorp (USA) Immuno-oncology Diagnosis Product and Services
Table 68. LabCorp (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. LabCorp (USA) Recent Developments/Updates
Table 70. LabCorp (USA) Competitive Strengths & Weaknesses
Table 71. NeoGenomics (USA) Basic Information, Manufacturing Base and Competitors
Table 72. NeoGenomics (USA) Major Business
Table 73. NeoGenomics (USA) Immuno-oncology Diagnosis Product and Services
Table 74. NeoGenomics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. NeoGenomics (USA) Recent Developments/Updates
Table 76. NeoGenomics (USA) Competitive Strengths & Weaknesses
Table 77. Myriad Genetics (USA) Basic Information, Manufacturing Base and Competitors
Table 78. Myriad Genetics (USA) Major Business
Table 79. Myriad Genetics (USA) Immuno-oncology Diagnosis Product and Services
Table 80. Myriad Genetics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Myriad Genetics (USA) Recent Developments/Updates
Table 82. Myriad Genetics (USA) Competitive Strengths & Weaknesses
Table 83. Caris Life Sciences (USA) Basic Information, Manufacturing Base and Competitors
Table 84. Caris Life Sciences (USA) Major Business
Table 85. Caris Life Sciences (USA) Immuno-oncology Diagnosis Product and Services
Table 86. Caris Life Sciences (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Caris Life Sciences (USA) Recent Developments/Updates
Table 88. Caris Life Sciences (USA) Competitive Strengths & Weaknesses
Table 89. Roche (Switzerland) Basic Information, Manufacturing Base and Competitors
Table 90. Roche (Switzerland) Major Business
Table 91. Roche (Switzerland) Immuno-oncology Diagnosis Product and Services
Table 92. Roche (Switzerland) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Roche (Switzerland) Recent Developments/Updates
Table 94. Roche (Switzerland) Competitive Strengths & Weaknesses
Table 95. BioM?rieux (France) Basic Information, Manufacturing Base and Competitors
Table 96. BioM?rieux (France) Major Business
Table 97. BioM?rieux (France) Immuno-oncology Diagnosis Product and Services
Table 98. BioM?rieux (France) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. BioM?rieux (France) Recent Developments/Updates
Table 100. BioM?rieux (France) Competitive Strengths & Weaknesses
Table 101. QIAGEN (Netherlands) Basic Information, Manufacturing Base and Competitors
Table 102. QIAGEN (Netherlands) Major Business
Table 103. QIAGEN (Netherlands) Immuno-oncology Diagnosis Product and Services
Table 104. QIAGEN (Netherlands) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. QIAGEN (Netherlands) Recent Developments/Updates
Table 106. QIAGEN (Netherlands) Competitive Strengths & Weaknesses
Table 107. Burning Rock Biotech (China) Basic Information, Manufacturing Base and Competitors
Table 108. Burning Rock Biotech (China) Major Business
Table 109. Burning Rock Biotech (China) Immuno-oncology Diagnosis Product and Services
Table 110. Burning Rock Biotech (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Burning Rock Biotech (China) Recent Developments/Updates
Table 112. Burning Rock Biotech (China) Competitive Strengths & Weaknesses
Table 113. Novogene (China) Basic Information, Manufacturing Base and Competitors
Table 114. Novogene (China) Major Business
Table 115. Novogene (China) Immuno-oncology Diagnosis Product and Services
Table 116. Novogene (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Novogene (China) Recent Developments/Updates
Table 118. Novogene (China) Competitive Strengths & Weaknesses
Table 119. BGI Genomics (China) Basic Information, Manufacturing Base and Competitors
Table 120. BGI Genomics (China) Major Business
Table 121. BGI Genomics (China) Immuno-oncology Diagnosis Product and Services
Table 122. BGI Genomics (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. BGI Genomics (China) Recent Developments/Updates
Table 124. BGI Genomics (China) Competitive Strengths & Weaknesses
Table 125. Sysmex (Japan) Basic Information, Manufacturing Base and Competitors
Table 126. Sysmex (Japan) Major Business
Table 127. Sysmex (Japan) Immuno-oncology Diagnosis Product and Services
Table 128. Sysmex (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Sysmex (Japan) Recent Developments/Updates
Table 130. Sysmex (Japan) Competitive Strengths & Weaknesses
Table 131. Fujirebio (Japan) Basic Information, Manufacturing Base and Competitors
Table 132. Fujirebio (Japan) Major Business
Table 133. Fujirebio (Japan) Immuno-oncology Diagnosis Product and Services
Table 134. Fujirebio (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Fujirebio (Japan) Recent Developments/Updates
Table 136. Fujirebio (Japan) Competitive Strengths & Weaknesses
Table 137. IMBDx (South Korea) Basic Information, Manufacturing Base and Competitors
Table 138. IMBDx (South Korea) Major Business
Table 139. IMBDx (South Korea) Immuno-oncology Diagnosis Product and Services
Table 140. IMBDx (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. IMBDx (South Korea) Recent Developments/Updates
Table 142. IMBDx (South Korea) Competitive Strengths & Weaknesses
Table 143. Seegene (South Korea) Basic Information, Manufacturing Base and Competitors
Table 144. Seegene (South Korea) Major Business
Table 145. Seegene (South Korea) Immuno-oncology Diagnosis Product and Services
Table 146. Seegene (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Seegene (South Korea) Recent Developments/Updates
Table 148. Seegene (South Korea) Competitive Strengths & Weaknesses
Table 149. GeneMatrix (South Korea) Basic Information, Manufacturing Base and Competitors
Table 150. GeneMatrix (South Korea) Major Business
Table 151. GeneMatrix (South Korea) Immuno-oncology Diagnosis Product and Services
Table 152. GeneMatrix (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. GeneMatrix (South Korea) Recent Developments/Updates
Table 154. GeneMatrix (South Korea) Competitive Strengths & Weaknesses
Table 155. Global Key Players of Immuno-oncology Diagnosis Upstream (Raw Materials)
Table 156. Global Immuno-oncology Diagnosis Typical Customers
Table 1. World Immuno-oncology Diagnosis Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Immuno-oncology Diagnosis Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Immuno-oncology Diagnosis Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Immuno-oncology Diagnosis Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Immuno-oncology Diagnosis Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Immuno-oncology Diagnosis Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Immuno-oncology Diagnosis Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Immuno-oncology Diagnosis Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Immuno-oncology Diagnosis Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Immuno-oncology Diagnosis Players in 2025
Table 12. World Immuno-oncology Diagnosis Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Immuno-oncology Diagnosis Company Evaluation Quadrant
Table 14. Head Office of Key Immuno-oncology Diagnosis Players
Table 15. Immuno-oncology Diagnosis Market: Company Product Type Footprint
Table 16. Immuno-oncology Diagnosis Market: Company Product Application Footprint
Table 17. Immuno-oncology Diagnosis Mergers & Acquisitions Activity
Table 18. United States VS China Immuno-oncology Diagnosis Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Immuno-oncology Diagnosis Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Immuno-oncology Diagnosis Companies, Headquarters (States, Country)
Table 21. United States Based Companies Immuno-oncology Diagnosis Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Immuno-oncology Diagnosis Revenue Market Share (2021-2026)
Table 23. China Based Immuno-oncology Diagnosis Companies, Headquarters (Province, Country)
Table 24. China Based Companies Immuno-oncology Diagnosis Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Immuno-oncology Diagnosis Revenue Market Share (2021-2026)
Table 26. Rest of World Based Immuno-oncology Diagnosis Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Immuno-oncology Diagnosis Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Immuno-oncology Diagnosis Revenue Market Share (2021-2026)
Table 29. World Immuno-oncology Diagnosis Market Size by Technology Path, (USD Million), 2021 & 2025 & 2032
Table 30. World Immuno-oncology Diagnosis Market Size Value by Technology Path (2021-2026) & (USD Million)
Table 31. World Immuno-oncology Diagnosis Market Size by Technology Path (2027-2032) & (USD Million)
Table 32. World Immuno-oncology Diagnosis Market Size by Detection Biomarkers, (USD Million), 2021 & 2025 & 2032
Table 33. World Immuno-oncology Diagnosis Market Size Value by Detection Biomarkers (2021-2026) & (USD Million)
Table 34. World Immuno-oncology Diagnosis Market Size by Detection Biomarkers (2027-2032) & (USD Million)
Table 35. World Immuno-oncology Diagnosis Market Size by Use Scenarios, (USD Million), 2021 & 2025 & 2032
Table 36. World Immuno-oncology Diagnosis Market Size Value by Use Scenarios (2021-2026) & (USD Million)
Table 37. World Immuno-oncology Diagnosis Market Size by Use Scenarios (2027-2032) & (USD Million)
Table 38. World Immuno-oncology Diagnosis Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Immuno-oncology Diagnosis Market Size by Application (2021-2026) & (USD Million)
Table 40. World Immuno-oncology Diagnosis Market Size by Application (2027-2032) & (USD Million)
Table 41. Guardant Health (USA) Basic Information, Manufacturing Base and Competitors
Table 42. Guardant Health (USA) Major Business
Table 43. Guardant Health (USA) Immuno-oncology Diagnosis Product and Services
Table 44. Guardant Health (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Guardant Health (USA) Recent Developments/Updates
Table 46. Guardant Health (USA) Competitive Strengths & Weaknesses
Table 47. Foundation Medicine (USA) Basic Information, Manufacturing Base and Competitors
Table 48. Foundation Medicine (USA) Major Business
Table 49. Foundation Medicine (USA) Immuno-oncology Diagnosis Product and Services
Table 50. Foundation Medicine (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Foundation Medicine (USA) Recent Developments/Updates
Table 52. Foundation Medicine (USA) Competitive Strengths & Weaknesses
Table 53. Illumina (USA) Basic Information, Manufacturing Base and Competitors
Table 54. Illumina (USA) Major Business
Table 55. Illumina (USA) Immuno-oncology Diagnosis Product and Services
Table 56. Illumina (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Illumina (USA) Recent Developments/Updates
Table 58. Illumina (USA) Competitive Strengths & Weaknesses
Table 59. Thermo Fisher Scientific (USA) Basic Information, Manufacturing Base and Competitors
Table 60. Thermo Fisher Scientific (USA) Major Business
Table 61. Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Product and Services
Table 62. Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Thermo Fisher Scientific (USA) Recent Developments/Updates
Table 64. Thermo Fisher Scientific (USA) Competitive Strengths & Weaknesses
Table 65. LabCorp (USA) Basic Information, Manufacturing Base and Competitors
Table 66. LabCorp (USA) Major Business
Table 67. LabCorp (USA) Immuno-oncology Diagnosis Product and Services
Table 68. LabCorp (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. LabCorp (USA) Recent Developments/Updates
Table 70. LabCorp (USA) Competitive Strengths & Weaknesses
Table 71. NeoGenomics (USA) Basic Information, Manufacturing Base and Competitors
Table 72. NeoGenomics (USA) Major Business
Table 73. NeoGenomics (USA) Immuno-oncology Diagnosis Product and Services
Table 74. NeoGenomics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. NeoGenomics (USA) Recent Developments/Updates
Table 76. NeoGenomics (USA) Competitive Strengths & Weaknesses
Table 77. Myriad Genetics (USA) Basic Information, Manufacturing Base and Competitors
Table 78. Myriad Genetics (USA) Major Business
Table 79. Myriad Genetics (USA) Immuno-oncology Diagnosis Product and Services
Table 80. Myriad Genetics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Myriad Genetics (USA) Recent Developments/Updates
Table 82. Myriad Genetics (USA) Competitive Strengths & Weaknesses
Table 83. Caris Life Sciences (USA) Basic Information, Manufacturing Base and Competitors
Table 84. Caris Life Sciences (USA) Major Business
Table 85. Caris Life Sciences (USA) Immuno-oncology Diagnosis Product and Services
Table 86. Caris Life Sciences (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Caris Life Sciences (USA) Recent Developments/Updates
Table 88. Caris Life Sciences (USA) Competitive Strengths & Weaknesses
Table 89. Roche (Switzerland) Basic Information, Manufacturing Base and Competitors
Table 90. Roche (Switzerland) Major Business
Table 91. Roche (Switzerland) Immuno-oncology Diagnosis Product and Services
Table 92. Roche (Switzerland) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Roche (Switzerland) Recent Developments/Updates
Table 94. Roche (Switzerland) Competitive Strengths & Weaknesses
Table 95. BioM?rieux (France) Basic Information, Manufacturing Base and Competitors
Table 96. BioM?rieux (France) Major Business
Table 97. BioM?rieux (France) Immuno-oncology Diagnosis Product and Services
Table 98. BioM?rieux (France) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. BioM?rieux (France) Recent Developments/Updates
Table 100. BioM?rieux (France) Competitive Strengths & Weaknesses
Table 101. QIAGEN (Netherlands) Basic Information, Manufacturing Base and Competitors
Table 102. QIAGEN (Netherlands) Major Business
Table 103. QIAGEN (Netherlands) Immuno-oncology Diagnosis Product and Services
Table 104. QIAGEN (Netherlands) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. QIAGEN (Netherlands) Recent Developments/Updates
Table 106. QIAGEN (Netherlands) Competitive Strengths & Weaknesses
Table 107. Burning Rock Biotech (China) Basic Information, Manufacturing Base and Competitors
Table 108. Burning Rock Biotech (China) Major Business
Table 109. Burning Rock Biotech (China) Immuno-oncology Diagnosis Product and Services
Table 110. Burning Rock Biotech (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Burning Rock Biotech (China) Recent Developments/Updates
Table 112. Burning Rock Biotech (China) Competitive Strengths & Weaknesses
Table 113. Novogene (China) Basic Information, Manufacturing Base and Competitors
Table 114. Novogene (China) Major Business
Table 115. Novogene (China) Immuno-oncology Diagnosis Product and Services
Table 116. Novogene (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Novogene (China) Recent Developments/Updates
Table 118. Novogene (China) Competitive Strengths & Weaknesses
Table 119. BGI Genomics (China) Basic Information, Manufacturing Base and Competitors
Table 120. BGI Genomics (China) Major Business
Table 121. BGI Genomics (China) Immuno-oncology Diagnosis Product and Services
Table 122. BGI Genomics (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. BGI Genomics (China) Recent Developments/Updates
Table 124. BGI Genomics (China) Competitive Strengths & Weaknesses
Table 125. Sysmex (Japan) Basic Information, Manufacturing Base and Competitors
Table 126. Sysmex (Japan) Major Business
Table 127. Sysmex (Japan) Immuno-oncology Diagnosis Product and Services
Table 128. Sysmex (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Sysmex (Japan) Recent Developments/Updates
Table 130. Sysmex (Japan) Competitive Strengths & Weaknesses
Table 131. Fujirebio (Japan) Basic Information, Manufacturing Base and Competitors
Table 132. Fujirebio (Japan) Major Business
Table 133. Fujirebio (Japan) Immuno-oncology Diagnosis Product and Services
Table 134. Fujirebio (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Fujirebio (Japan) Recent Developments/Updates
Table 136. Fujirebio (Japan) Competitive Strengths & Weaknesses
Table 137. IMBDx (South Korea) Basic Information, Manufacturing Base and Competitors
Table 138. IMBDx (South Korea) Major Business
Table 139. IMBDx (South Korea) Immuno-oncology Diagnosis Product and Services
Table 140. IMBDx (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. IMBDx (South Korea) Recent Developments/Updates
Table 142. IMBDx (South Korea) Competitive Strengths & Weaknesses
Table 143. Seegene (South Korea) Basic Information, Manufacturing Base and Competitors
Table 144. Seegene (South Korea) Major Business
Table 145. Seegene (South Korea) Immuno-oncology Diagnosis Product and Services
Table 146. Seegene (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Seegene (South Korea) Recent Developments/Updates
Table 148. Seegene (South Korea) Competitive Strengths & Weaknesses
Table 149. GeneMatrix (South Korea) Basic Information, Manufacturing Base and Competitors
Table 150. GeneMatrix (South Korea) Major Business
Table 151. GeneMatrix (South Korea) Immuno-oncology Diagnosis Product and Services
Table 152. GeneMatrix (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. GeneMatrix (South Korea) Recent Developments/Updates
Table 154. GeneMatrix (South Korea) Competitive Strengths & Weaknesses
Table 155. Global Key Players of Immuno-oncology Diagnosis Upstream (Raw Materials)
Table 156. Global Immuno-oncology Diagnosis Typical Customers
LIST OF FIGURES
Figure 1. Immuno-oncology Diagnosis Picture
Figure 2. World Immuno-oncology Diagnosis Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Immuno-oncology Diagnosis Total Revenue (2021-2032) & (USD Million)
Figure 4. World Immuno-oncology Diagnosis Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Immuno-oncology Diagnosis Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 13. Immuno-oncology Diagnosis Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 16. World Immuno-oncology Diagnosis Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 18. China Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 23. India Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Immuno-oncology Diagnosis by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Immuno-oncology Diagnosis Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Immuno-oncology Diagnosis Markets in 2025
Figure 27. United States VS China: Immuno-oncology Diagnosis Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Immuno-oncology Diagnosis Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Immuno-oncology Diagnosis Market Size by Technology Path, (USD Million), 2021 & 2025 & 2032
Figure 30. World Immuno-oncology Diagnosis Market Size Market Share by Technology Path in 2025
Figure 31. Immunohistochemistry
Figure 32. Molecular Diagnostics
Figure 33. High-Throughput Sequencing
Figure 34. Liquid Biopsy
Figure 35. Multi-omics Integrated Analysis
Figure 36. World Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2032)
Figure 37. World Immuno-oncology Diagnosis Market Size by Detection Biomarkers, (USD Million), 2021 & 2025 & 2032
Figure 38. World Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers in 2025
Figure 39. Immune Checkpoint Biomarkers
Figure 40. Tumor Mutation Burden
Figure 41. Microsatellite Instability
Figure 42. Tumor-Infiltrating Lymphocytes
Figure 43. Immune-Related Gene Expression Profiling
Figure 44. World Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers (2021-2032)
Figure 45. World Immuno-oncology Diagnosis Market Size by Use Scenarios, (USD Million), 2021 & 2025 & 2032
Figure 46. World Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios in 2025
Figure 47. Immunodiagnostics for Solid Tumors
Figure 48. Immunodiagnostics for Hematologic Malignancies
Figure 49. Tumor Microenvironment (TME) Analysis
Figure 50. World Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios (2021-2032)
Figure 51. World Immuno-oncology Diagnosis Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 52. World Immuno-oncology Diagnosis Market Size Market Share by Application in 2025
Figure 53. Research
Figure 54. Diagnostics
Figure 55. World Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2032)
Figure 56. Immuno-oncology Diagnosis Industrial Chain
Figure 57. Methodology
Figure 58. Research Process and Data Source
Figure 1. Immuno-oncology Diagnosis Picture
Figure 2. World Immuno-oncology Diagnosis Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Immuno-oncology Diagnosis Total Revenue (2021-2032) & (USD Million)
Figure 4. World Immuno-oncology Diagnosis Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Immuno-oncology Diagnosis Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Immuno-oncology Diagnosis Revenue (2021-2032) & (USD Million)
Figure 13. Immuno-oncology Diagnosis Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 16. World Immuno-oncology Diagnosis Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 18. China Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 23. India Immuno-oncology Diagnosis Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Immuno-oncology Diagnosis by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Immuno-oncology Diagnosis Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Immuno-oncology Diagnosis Markets in 2025
Figure 27. United States VS China: Immuno-oncology Diagnosis Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Immuno-oncology Diagnosis Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Immuno-oncology Diagnosis Market Size by Technology Path, (USD Million), 2021 & 2025 & 2032
Figure 30. World Immuno-oncology Diagnosis Market Size Market Share by Technology Path in 2025
Figure 31. Immunohistochemistry
Figure 32. Molecular Diagnostics
Figure 33. High-Throughput Sequencing
Figure 34. Liquid Biopsy
Figure 35. Multi-omics Integrated Analysis
Figure 36. World Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2032)
Figure 37. World Immuno-oncology Diagnosis Market Size by Detection Biomarkers, (USD Million), 2021 & 2025 & 2032
Figure 38. World Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers in 2025
Figure 39. Immune Checkpoint Biomarkers
Figure 40. Tumor Mutation Burden
Figure 41. Microsatellite Instability
Figure 42. Tumor-Infiltrating Lymphocytes
Figure 43. Immune-Related Gene Expression Profiling
Figure 44. World Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers (2021-2032)
Figure 45. World Immuno-oncology Diagnosis Market Size by Use Scenarios, (USD Million), 2021 & 2025 & 2032
Figure 46. World Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios in 2025
Figure 47. Immunodiagnostics for Solid Tumors
Figure 48. Immunodiagnostics for Hematologic Malignancies
Figure 49. Tumor Microenvironment (TME) Analysis
Figure 50. World Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios (2021-2032)
Figure 51. World Immuno-oncology Diagnosis Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 52. World Immuno-oncology Diagnosis Market Size Market Share by Application in 2025
Figure 53. Research
Figure 54. Diagnostics
Figure 55. World Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2032)
Figure 56. Immuno-oncology Diagnosis Industrial Chain
Figure 57. Methodology
Figure 58. Research Process and Data Source
